NCT07003737 Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation Status RECRUITING Phase NA
NCT06991920 Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage Status NOT_YET_RECRUITING Phase NA
NCT06882057 Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol Status RECRUITING Phase PHASE2/PHASE3
NCT06836973 Blinatumomab for Treatment of Refractory Myasthenia Gravis Status NOT_YET_RECRUITING Phase PHASE2/PHASE3
NCT06763302 NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL Status NOT_YET_RECRUITING Phase NA
NCT06684184 Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) Status NOT_YET_RECRUITING Phase PHASE2/PHASE3
NCT06658938 Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation Status NOT_YET_RECRUITING Phase NA
NCT06649422 Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study Status NOT_YET_RECRUITING Phase N/A
NCT06649006 Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL) Status COMPLETED Phase PHASE1
NCT06607419 Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia Status RECRUITING Phase PHASE2/PHASE3
NCT06570798 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases Status RECRUITING Phase PHASE2
NCT06554626 Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL Status RECRUITING Phase PHASE2
NCT06533748 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Status RECRUITING Phase PHASE2
NCT06504186 The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation Status NOT_YET_RECRUITING Phase NA
NCT06387121 Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL Status RECRUITING Phase PHASE2
NCT06339775 Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation Status RECRUITING Phase PHASE4
NCT06317662 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Status RECRUITING Phase PHASE2
NCT06308588 Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Status RECRUITING Phase PHASE1/PHASE2
NCT06287229 Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab Status RECRUITING Phase PHASE1/PHASE2